2020-01-21
Aphios Corporation, a UK-based green biotechnology company working on advanced drug delivery platforms and enhanced therapeutic products, recently succeeded in filing a US patent for the oral administration of Bryostatin-1 nanoparticles as the treatment of neurodegenerative diseases including Huntington’s disease, Parkinson's disease, Multiple Sclerosis, Down syndrome, and Alzheimer's disease.
